Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis

Authors

Jonathan Cooper, Cornell University
Qingwen Xu, University of Texas MD Anderson Cancer Center
Lu Zhou
Milica Pavlovic, Memorial Sloan-Kettering Cancer Center
Virginia Ojeda, Memorial Sloan-Kettering Cancer Center
Kamalika Moulick, Memorial Sloan-Kettering Cancer Center
Stanchina E de
John T. Poirier, Memorial Sloan-Kettering Cancer Center
Marjorie Zauderer, Cornell University
Charles M. Rudin, Memorial Sloan-Kettering Cancer Center
Matthias A. Karajannis, Memorial Sloan-Kettering Cancer Center
C. Oliver Hanemann, Peninsula Medical School
Filippo G. Giancotti, University of Texas MD Anderson Cancer Center

ORCID

• C. Oliver Hanemann: 0000-0002-1951-1025

DOI

10.1158/1535-7163.MCT-16-0821

Publication Date

2017-05-03

Publication Title

Molecular Cancer Therapeutics

ISSN

1535-7163

Embargo Period

2018-05-03

First Page

2016

Last Page

2016

Recommended Citation

Cooper, J., Xu, Q., Zhou, L., Pavlovic, M., Ojeda, V., Moulick, K., de, S., Poirier, J., Zauderer, M., Rudin, C., Karajannis, M., Hanemann, C., & Giancotti, F. (2017) 'Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis', Molecular Cancer Therapeutics, , pp. 2016-2016. Available at: 10.1158/1535-7163.MCT-16-0821